Davis M, Buse J et al ADA 2018; June 22–26, 2018; Orlando, Florida
Draft Consensus Recommendation – new since 2015
Consider important comorbidities that should influence the choice of a
particular glucose-lowering medication.
Among patients with type 2 diabetes with established atherosclerotic
cardiovascular disease (ASCVD), sodium-glucose cotransporter 2 (SGLT2) inhibitors or glucagon-Iike peptide 1 (GLP-1) receptor agonistswith proven cardiovascular benefit are recommended as part of glycemic management